Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

  • Lisa A. de Jong,
  • Jessie Groeneveld,
  • Jelena Stevanovic,
  • Harrie Rila,
  • Robert G. Tieleman,
  • Menno V. Huisman,
  • Maarten J. Postma,
  • Marinus van Hulst

Following the publication of this article [1] the authors received additional information that a correction [2] was published on an article [3] which the authors used for the real-world data (RWD) analysis. The authors were notified that a proportion of Medicare patients from the CMS database were unintentionally omitted from the original analysis [3]. The published corrected study [2] now incorporates the complete dataset.

As a result, the authors have re-analyzed the RWD-based analysis based on the corrected dataset reported in [2]. This has resulted in numerical changes to the outcomes of RWD analyses, which are reflected in the updated versions of Fig 3, Tables 3, 4 and 5, and Supporting Information files provided with this notice.

thumbnail
Download:
Fig 3. Probability of being the most cost-effective treatment choice per willingness-to-pay threshold for the RWD-based analysis.

Abbreviations: QALY, quality adjusted life-years; RWD, real-world data; VKA, vitamin K antagonist. threshold for the RWD-based analysis.

https://doi.org/10.1371/journal.pone.0266625.g001

thumbnail
Download:
Table 3. Base-case costs outcomes of the NMA-based and RWD-based analyses presented as costs per patient over a lifetime horizon.

https://doi.org/10.1371/journal.pone.0266625.t001

thumbnail
Download:
Table 4. Base-case results of the NMA-based and RWD-based analyses comparing apixaban to VKA and other NOACs.

https://doi.org/10.1371/journal.pone.0266625.t002

thumbnail
Download:
Table 5. Results of the scenario analyses: NMA-based and RWD-based analyses calculated from healthcare payer’s perspective (scenario 1), equal drugs costs for NOACs (scenario 2) and equal event unrelated AC discontinuation rates for NOACs and VKAs (scenario 3).

https://doi.org/10.1371/journal.pone.0266625.t003

Statements in [1] that were affected by the re-analysis are listed and corrected in the table below titled, “Table 6. Text Corrections”. In this table, reference 12a is used to designate Lip et al. (2020) (listed as reference [2] in this Correction).

thumbnail
Download:
Table 6. Text Corrections.

https://doi.org/10.1371/journal.pone.0266625.t004

The S3 Table legend in [1] cited reference 3 for Lip et al. (2018), which aligns with the reference number in S1 Appendix rather than the reference number in the article’s main reference list. The legend has been updated, below, to cite publication years for the Lip et al. article (2018) and correction (2020) [2].

An Editorial Board member has reviewed the updates to the RWD-based analysis and determined that the conclusions of article [1] are upheld.

Supporting information

The following are corrected versions of the Supporting Information files reported in [1].

S1 Table. Patient baseline characteristics model inputs used in the NMA-based and RWD-based analyses.

https://doi.org/10.1371/journal.pone.0266625.s001

(DOCX)

S2 Table. Event rates for apixaban and VKA and dabigatran 110 mg, dabigatran 150 mg, rivaroxaban, and edoxaban and distributions of patients across different levels of ischaemic and haemorrhagic stroke severity.

https://doi.org/10.1371/journal.pone.0266625.s002

(DOCX)

S3 Table. Input parameters for the RWD-based analysis obtained from real-world study comparing apixaban with VKA and other NOACs by Lip et al. (2018, 2020).

https://doi.org/10.1371/journal.pone.0266625.s003

(DOCX)

S4 Table. Background mortality, case fatality and mortality risk adjustment factors per event.

https://doi.org/10.1371/journal.pone.0266625.s004

(DOCX)

S5 Table. Event rates per 100 patient-years for no treatment after event unrelated treatment discontinuation.

https://doi.org/10.1371/journal.pone.0266625.s005

(DOCX)

S1 File. Probabilistic sensitivity analysis results.

https://doi.org/10.1371/journal.pone.0266625.s006

(DOCX)

References

  1. 1. de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, et al. (2019) Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE 14(9): e0222658. https://doi.org/10.1371/journal.pone.0222658 pmid:31527894
  2. 2. Correction to: Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: The ARISTOPHANES study. Stroke. 2020;51(4):e71http://dx.doi.org/10.1161/STR.0000000000000227 pmid:32202989
  3. 3. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke. 2018;49(12):2933–44. http://dx.doi.org/10.1161/STROKEAHA.118.020232 pmid:30571400

Citation: de Jong LA, Groeneveld J, Stevanovic J, Rila H, Tieleman RG, Huisman MV, et al. (2022) Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. PLoS ONE 17(3): e0266625. https://doi.org/10.1371/journal.pone.0266625

Published: March 31, 2022

Copyright: © 2022 de Jong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.